Cargando…

Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis

INTRODUCTION: Individual patients with rheumatoid arthritis (RA) show divergent specific anti-citrullinated protein/peptide antibodies (ACPA) patterns, but hitherto no individual ACPA specificity has consistently been linked to RA pathogenesis. ACPA are also implicated in immune complexes (IC)-assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohrabian, Azita, Mathsson-Alm, Linda, Hansson, Monika, Knight, Ann, Lysholm, Jörgen, Cornillet, Martin, Skriner, Karl, Serre, Guy, Larsson, Anders, Weitoft, Tomas, Rönnelid, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104681/
https://www.ncbi.nlm.nih.gov/pubmed/29895567
http://dx.doi.org/10.1136/annrheumdis-2017-212627
_version_ 1783349534158487552
author Sohrabian, Azita
Mathsson-Alm, Linda
Hansson, Monika
Knight, Ann
Lysholm, Jörgen
Cornillet, Martin
Skriner, Karl
Serre, Guy
Larsson, Anders
Weitoft, Tomas
Rönnelid, Johan
author_facet Sohrabian, Azita
Mathsson-Alm, Linda
Hansson, Monika
Knight, Ann
Lysholm, Jörgen
Cornillet, Martin
Skriner, Karl
Serre, Guy
Larsson, Anders
Weitoft, Tomas
Rönnelid, Johan
author_sort Sohrabian, Azita
collection PubMed
description INTRODUCTION: Individual patients with rheumatoid arthritis (RA) show divergent specific anti-citrullinated protein/peptide antibodies (ACPA) patterns, but hitherto no individual ACPA specificity has consistently been linked to RA pathogenesis. ACPA are also implicated in immune complexes (IC)-associated joint pathology, but until now, there has been no method to investigate the role of individual ACPA in RA IC formation and IC-associated pathogenesis. METHODS: We have developed a new technique based on IC binding to C1q-coated magnetic beads to purify and solubilise circulating IC in sera and synovial fluids (SF) from 77 patients with RA. This was combined with measurement of 19 individual ACPA in serum, SF and in the IC fractions from serum and SF. We investigated whether occurrence of individual ACPA as well as number of ACPA in these compartments was related to clinical and laboratory measures of disease activity and inflammation. RESULTS: The majority of individual ACPA reactivities were enriched in SF as compared with in serum, and levels of ACPA in IC were regulated independently of levels in serum and SF. No individual ACPA reactivity in any compartment showed a dominating association to clinical and laboratory measures of disease activity and severity. Instead, the number of individual ACPA reactivities in the IC fraction from SF associated with a number of markers of joint destruction and inflammation. CONCLUSIONS: Our data highlight the polyclonality of ACPA in joint IC and the possibility that a broad ACPA repertoire in synovial fluid IC might drive the local inflammatory and matrix-degrading processes in joints, in analogy with antibody-induced rodent arthritis models.
format Online
Article
Text
id pubmed-6104681
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-61046812018-08-24 Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis Sohrabian, Azita Mathsson-Alm, Linda Hansson, Monika Knight, Ann Lysholm, Jörgen Cornillet, Martin Skriner, Karl Serre, Guy Larsson, Anders Weitoft, Tomas Rönnelid, Johan Ann Rheum Dis Basic and Translational Research INTRODUCTION: Individual patients with rheumatoid arthritis (RA) show divergent specific anti-citrullinated protein/peptide antibodies (ACPA) patterns, but hitherto no individual ACPA specificity has consistently been linked to RA pathogenesis. ACPA are also implicated in immune complexes (IC)-associated joint pathology, but until now, there has been no method to investigate the role of individual ACPA in RA IC formation and IC-associated pathogenesis. METHODS: We have developed a new technique based on IC binding to C1q-coated magnetic beads to purify and solubilise circulating IC in sera and synovial fluids (SF) from 77 patients with RA. This was combined with measurement of 19 individual ACPA in serum, SF and in the IC fractions from serum and SF. We investigated whether occurrence of individual ACPA as well as number of ACPA in these compartments was related to clinical and laboratory measures of disease activity and inflammation. RESULTS: The majority of individual ACPA reactivities were enriched in SF as compared with in serum, and levels of ACPA in IC were regulated independently of levels in serum and SF. No individual ACPA reactivity in any compartment showed a dominating association to clinical and laboratory measures of disease activity and severity. Instead, the number of individual ACPA reactivities in the IC fraction from SF associated with a number of markers of joint destruction and inflammation. CONCLUSIONS: Our data highlight the polyclonality of ACPA in joint IC and the possibility that a broad ACPA repertoire in synovial fluid IC might drive the local inflammatory and matrix-degrading processes in joints, in analogy with antibody-induced rodent arthritis models. BMJ Publishing Group 2018-09 2018-06-12 /pmc/articles/PMC6104681/ /pubmed/29895567 http://dx.doi.org/10.1136/annrheumdis-2017-212627 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Basic and Translational Research
Sohrabian, Azita
Mathsson-Alm, Linda
Hansson, Monika
Knight, Ann
Lysholm, Jörgen
Cornillet, Martin
Skriner, Karl
Serre, Guy
Larsson, Anders
Weitoft, Tomas
Rönnelid, Johan
Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
title Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
title_full Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
title_fullStr Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
title_full_unstemmed Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
title_short Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
title_sort number of individual acpa reactivities in synovial fluid immune complexes, but not serum anti-ccp2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
topic Basic and Translational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104681/
https://www.ncbi.nlm.nih.gov/pubmed/29895567
http://dx.doi.org/10.1136/annrheumdis-2017-212627
work_keys_str_mv AT sohrabianazita numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT mathssonalmlinda numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT hanssonmonika numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT knightann numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT lysholmjorgen numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT cornilletmartin numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT skrinerkarl numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT serreguy numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT larssonanders numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT weitofttomas numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis
AT ronnelidjohan numberofindividualacpareactivitiesinsynovialfluidimmunecomplexesbutnotserumanticcp2levelsassociatewithinflammationandjointdestructioninrheumatoidarthritis